“The haematopoietic system is constantly formed by the differentiation of stem cells into specialised cells,” started Dr Nili Furer (Weizmann Institute of Science, Israel). “While we have established reference values for matured cells, we do not have relevant reference values for progenitor states. We need to capture these values to know which values are part of healthy variation and what values may be related to diseases.” For this purpose, Dr Furer and co-investigators analysed HSPCs from peripheral blood samples from 99 individuals [1].
In total, 360,000 single cells were retrieved and categorised as common lymphoid progenitors or multipotent myeloid progenitors. Dr Furer commented that the inter-individual variation in circulating HPSCs is large in healthy individuals (see Figure), whereas intra-individual cell type frequencies were stable across time. The generated data was then applied as a healthy reference map. Using HSPCs derived from blood samples of 100 cytopenic study participants and an additional 100 healthy participants, they validated their atlas and compared healthy and diseased states. Indeed, the additional set of 100 samples from healthy individuals fitted in the healthy variation of the reference map, whereas progressive dissimilarities were seen in cytopenic patients, validating their unique dataset.
Figure: Inter-individual variation in circulating HSPC compositions in healthy individuals [1]
BEMP, basophil eosinophil mast progenitor; ERYP, primitive erythroid cells; MEP(-L-E), megakaryocyte-erythroid progenitors (-L-E); GMP, granulocyte-macrophage progenitors; MPP, multipotent progenitors; HSC, hematopoietic stem cells; CLP(-E-M-L), common lymphoid progenitors (-E-M-L); NKTDP, natural killer- T-and dendritic cell progenitors.
- Furer N, et al. Natural and age-related variation in circulating human hematopoietic stem cells. Plenary abstracts session, EHA 2023 Annual Congress, 8─11 June, Frankfurt, Germany.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« High risk of death for individuals with C282Y/C282Y hereditary haemochromatosis and diabetes Next Article
REVIVE: Rusfertide meets the primary endpoint in PV »
« High risk of death for individuals with C282Y/C282Y hereditary haemochromatosis and diabetes Next Article
REVIVE: Rusfertide meets the primary endpoint in PV »
Table of Contents: EHA 2023
Featured articles
Multiple Myeloma
Can we combine teclistamab and nirogacestat for the treatment of RRMM?
Encouraging results for low-dose belantamab mafodotin plus nirogacestat in patients with RRMM
CARTITUDE-4: Cilta-cel meets expectations in lenalidomide-refractory MM
Lymphoma
Radiotherapy or not in patients with PMBCL after immunochemotherapy?
Durable responses for loncastuximab tesirine in relapsed/refractory DLBCL
Zandelisib promising in relapsed/refractory indolent B-cell NHL
Promising data for epcoritamab plus R-CHOP in untreated DLBCL
Non-Malignant Haematology
Investigational agent OMS906 performs well in PNH
Robust platelet responses with cevidoplenib in ITP
Leukaemia
QuANTUM-First: Updated results on quizartinib in AML with FLT3-ITD
Promising data for ziftomenib in relapsed/refractory NPM1-mutated AML
MRD-positive patients with FLT3-ITD AML may benefit from post-transplant gilteritinib
Deep responses with asciminib in CML-CP
QUIWI: First results suggest a clinical benefit of quizartinib in AML
Miscellaneous
COMMANDS trial: A paradigm shift in LR-MDS-associated anaemia
REVIVE: Rusfertide meets the primary endpoint in PV
Mapping healthy HPSC variations to diagnose haematopoietic abnormalities
High risk of death for individuals with C282Y/C282Y hereditary haemochromatosis and diabetes
Related Articles
February 26, 2020
Phase 3 BETonMACE trial did not meet its primary endpoint
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com